Acquired resistance to TKIs in solid tumours: learning from lung cancer
The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
W Pao, J Chmielecki - Nature Reviews Cancer, 2010 - nature.com
Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial
K Kelly, NK Altorki, WEE Eberhardt… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19
deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine …
deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine …
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
DB Costa, S Kobayashi, SS Pandya, WL Yeo… - Journal of Clinical …, 2011 - ascopubs.org
Discussion Crizotinib (molecular weight, 450.34) is an anaplastic lymphoma kinase (ALK)
tyrosine kinase inhibitor (TKI) 3 that leads to responses in most patients with NSCLC …
tyrosine kinase inhibitor (TKI) 3 that leads to responses in most patients with NSCLC …
Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling
Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets
There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM)
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …
[HTML][HTML] Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
S Kobayashi, HM Canepa, AS Bailey… - Journal of Thoracic …, 2013 - Elsevier
Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
Determining the optimal dose in the development of anticancer agents
RHJ Mathijssen, A Sparreboom, J Verweij - Nature reviews Clinical …, 2014 - nature.com
Identification of the optimal dose remains a key challenge in drug development. For cytotoxic
drugs, the standard approach is based on identifying the maximum tolerated dose (MTD) in …
drugs, the standard approach is based on identifying the maximum tolerated dose (MTD) in …